Literature DB >> 27993520

Overexpression of βCaMKII impairs behavioral flexibility and NMDAR-dependent long-term depression in the dentate gyrus.

Pengcheng Yin1, Hao Xu1, Qi Wang1, Jiayue Wang1, Liang Yin1, Meichen Xu1, Zhenyang Xie1, Wenzhao Liu1, Xiaohua Cao2.   

Abstract

Behavioral flexibility is in close proximity to dentate gyrus (DG) function and long-term depression (LTD), but the role of DG LTD in behavioral flexibility has hitherto been unexplored. Although the functions of alpha-Ca2+/calmodulin-dependent protein kinase II (CaMKII) have been studied extensively, the role of βCaMKII, a constituent of the CaMKII holoenzyme, in LTD and behavioral flexibility has not been investigated in vivo. Here using the βCaMKII-F90G transgenic (TG) mice, in which the inducible and reversible overexpression of βCaMKII is restricted to dentate gyrus (DG), we found that TG mice exhibited defective behavioral flexibility in two reversal tasks and seriously impaired N-methyl-d-aspartic acid receptor (NMDAR)-dependent LTD in DG medial perforant path (MPP). Consistent with the deficit in NMDAR-LTD, GluA1-Ser845, GluA1-Ser831 dephosphorylation and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) internalization were also disrupted during NMDAR-LTD in TG mice. Furthermore, these deficits were due to decreased activities of protein phosphatases (PP) 1/2A and glycogen synthesis kinase 3 beta (GSK3β), and overexpressed synaptic stargazin in TG mice. Importantly, all the deficits above could be reversed by 1-naphthylmethyl (NM)-PP1, a specific inhibitor of the exogenous βCaMKII-F90G. Taken together, our findings for the first time demonstrate that βCaMKII overexpression impairs behavioral flexibility and NMDAR-dependent LTD in DG MPP, which further confirms the close relationship between NMDAR-dependent LTD and behavioral flexibility.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMPA receptors; Behavioral flexibility; Dentate gyrus; Long-term depression; Protein phosphatases; βCaMKII

Mesh:

Substances:

Year:  2016        PMID: 27993520     DOI: 10.1016/j.neuropharm.2016.12.013

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.

Authors:  James A Timmons; Andrew Anighoro; Robert J Brogan; Jack Stahl; Claes Wahlestedt; David Gordon Farquhar; Jake Taylor-King; Claude-Henry Volmar; William E Kraus; Stuart M Phillips
Journal:  Elife       Date:  2022-01-17       Impact factor: 8.713

2.  A Novel CaMKII Inhibitory Peptide Blocks Relapse to Morphine Seeking by Influencing Synaptic Plasticity in the Nucleus Accumbens Shell.

Authors:  Zhuo Liu; Jianjun Zhang; Linqing Miao; Qingyao Kong; Xiaodong Liu; Longchuan Yu
Journal:  Brain Sci       Date:  2022-07-26

Review 3.  Role of Ca2+/Calmodulin-Dependent Protein Kinase Type II in Mediating Function and Dysfunction at Glutamatergic Synapses.

Authors:  Archana G Mohanan; Sowmya Gunasekaran; Reena Sarah Jacob; R V Omkumar
Journal:  Front Mol Neurosci       Date:  2022-06-20       Impact factor: 6.261

4.  αCaMKII in the lateral amygdala mediates PTSD-Like behaviors and NMDAR-Dependent LTD.

Authors:  Shuming An; Jiayue Wang; Xuliang Zhang; Yanhong Duan; Yiqiong Xu; Junyan Lv; Dasheng Wang; Huan Zhang; Gal Richter-Levin; Oded Klavir; Buwei Yu; Xiaohua Cao
Journal:  Neurobiol Stress       Date:  2021-06-23

Review 5.  CaMKIIβ in Neuronal Development and Plasticity: An Emerging Candidate in Brain Diseases.

Authors:  Olivier Nicole; Emilie Pacary
Journal:  Int J Mol Sci       Date:  2020-10-01       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.